Heart Test Laboratories, Inc. (HSCS) Income Statement
HSCS FY2026 at a glance
Fiscal year ended April 30, 2026 · U.S. dollarsHSCS revenue and net income
Where HSCS's revenue goes
FY2026Each bar shows an amount and its share of revenue. HSCS kept −211,666.5% of revenue as net income.
HSCS profit margins
HSCS growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −0.7% | −5.7% | −29.9% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
HSCS quarterly EPS vs estimates
Heart Test Laboratories beat the analyst EPS estimate in 5 of the last 8 quarters.
HSCS income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4,319 | $4,350 | $18,600 | $5,150 | $14,373 | $25,604 | $64,182 |
| Cost of revenue | $133,118 | $129,836 | $101,214 | $29,711 | $34,456 | $44,276 | $110,287 |
| Gross profit | −$128,799 | −$125,485 | −$82,614 | −$24,561 | −$20,083 | −$18,672 | −$46,105 |
| Research & development | $2.84B | $4.4M | $2.9M | $2.5M | $3.0M | $1.7M | $2.0M |
| Sales, general & admin | $9.9M | $4.0M | $3.4M | $3.7M | $1.7M | $874,620 | $1.8M |
| Total operating expenses | $8.3M | $8.2M | $6.2M | $6.1M | $4.7M | $2.5M | $3.8M |
| Operating income | −$8.4M | −$8.4M | −$6.3M | −$6.1M | −$4.7M | −$2.6M | −$3.8M |
| Interest expense | $753,041 | $500,453 | $354,080 | $243,174 | $371,619 | $132,454 | $2,811 |
| Income before taxes | −$9.1M | −$8.8M | −$6.6M | −$6.4M | −$4.8M | −$2.5M | −$3.8M |
| Income taxes | −$3.7M | — | −$95,133 | $484.5M | −$250,200 | $129,003 | $22,704 |
| Net income | −$9.1M | −$8.8M | −$6.6M | −$6.4M | −$4.8M | −$2.5M | −$3.8M |
| EBITDA | −$8.3M | −$8.2M | −$6.2M | −$6.0M | −$4.4M | −$2.3M | −$3.7M |
| EPS (diluted) | −$3.94 | −$9.36 | −$50.81 | −$57.46 | −$0.35 | −$74.08 | — |
| Gross margin | −2,982.1% | −2,884.7% | −444.2% | −476.9% | −139.7% | −72.9% | −71.8% |
| Operating margin | −194,787.4% | −192,013.1% | −33,902.0% | −118,698.3% | −32,765.6% | −10,030.2% | −5,949.0% |
| Net margin | −211,666.5% | −201,499.5% | −35,511.9% | −123,384.3% | −33,592.6% | −9,577.3% | −5,938.0% |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2,100 | $89.5M | $0 | $2,419 | $1,900 | $4,350 | $0 | $0 | $0 | $0 | $14,700 | $3,900 |
| Cost of revenue | $35,288 | $34,000 | $33,238 | $33,443 | $32,435 | $33,141 | $28,967 | $34,410 | $33,318 | $9,201 | $8,278 | $9,156 |
| Gross profit | −$33,188 | −$34,000 | −$33,238 | −$31,024 | −$30,535 | −$28,791 | −$28,967 | −$34,410 | −$33,318 | −$9,201 | $6,422 | −$5,256 |
| Research & development | $906.6M | $2.4M | $638,575 | $727,026 | $997,206 | $929,091 | $1.0M | $1.2M | $1.2M | $1.0M | $509,507 | $757,303 |
| Sales, general & admin | $2.0M | $9.9M | $1.3M | $1.3M | $878,053 | $993,778 | $1.3M | $786,068 | $850,736 | $833,678 | $1.0M | $815,020 |
| Total operating expenses | $2.9M | $2.5M | $1.9M | $2.0M | $1.8M | $1.9M | $2.3M | $2.0M | $2.1M | $1.9M | $1.5M | $1.6M |
| Operating income | −$2.9M | −$2.5M | −$1.9M | −$2.1M | −$1.9M | −$1.9M | −$2.4M | −$2.0M | −$2.1M | −$1.9M | −$1.5M | −$1.6M |
| Interest expense | $235,261 | $228,310 | $61,509 | $279,534 | $183,688 | $180,852 | $179,477 | $117,598 | $22,526 | $20,937 | $118,445 | $178,438 |
| Income before taxes | −$3.2M | −$2.8M | −$2.0M | −$2.4M | −$2.1M | −$2.1M | −$2.5M | −$2.1M | −$2.1M | −$1.8M | −$1.6M | −$1.7M |
| Income taxes | — | −$3.7M | — | — | — | — | — | — | $69,030 | $75,500 | $3 | $178,441 |
| Net income | −$3.2M | −$2.8M | −$2.0M | −$2.4M | −$2.1M | −$2.1M | −$2.5M | −$2.1M | −$2.1M | −$1.8M | −$1.6M | −$1.7M |
| EBITDA | −$2.9M | −$2.5M | −$1.9M | −$2.0M | −$1.8M | −$1.9M | −$2.3M | −$1.9M | −$2.0M | −$1.7M | −$1.5M | −$1.6M |
| EPS (diluted) | −$0.86 | −$0.88 | −$0.63 | −$0.85 | −$1.58 | −$1.88 | −$2.57 | −$2.27 | −$2.64 | −$18.81 | −$3.00 | −$16.00 |
| Gross margin | −1,580.4% | −0.0% | — | −1,282.5% | −1,607.1% | −661.9% | — | — | — | — | 43.7% | −134.8% |
| Operating margin | −139,956.7% | −2.8% | — | −85,713.2% | −98,637.8% | −44,147.1% | — | — | — | — | −10,376.7% | −40,254.9% |
| Net margin | −151,064.0% | −3.1% | — | −97,179.4% | −108,157.6% | −48,145.5% | — | — | — | — | −11,182.4% | −44,830.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in HSCS's financial statements (latest annual report filed June 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
HSCS financial results
In fiscal year 2026 (ended April 30, 2026), Heart Test Laboratories reported revenue of $0.0 million, down 0.7% from the year before. It had a net loss of $9.1 million, a net profit margin of −211,666.5%. Diluted earnings per share came to −$3.94. Over five years revenue grew at an average rate of −29.9% a year.
See the HSCS stock overview for the latest quote and news, or the HSCS chart for price history and technical indicators.
HSCS income statement FAQ
What is Heart Test Laboratories's annual revenue?
Heart Test Laboratories reported total revenue of $0.0 million for fiscal year 2026, which ended on April 30, 2026. That was down 0.7% from $0.0 million the previous year.
Is Heart Test Laboratories profitable?
No. Heart Test Laboratories reported a net loss of $9.1 million in fiscal 2026, a net profit margin of −211,666.5%; its operating margin was −194,787.4%.
What is Heart Test Laboratories's gross margin?
Heart Test Laboratories's gross margin was −2,982.1% in fiscal 2026: for every $100 of revenue, Heart Test Laboratories kept $-2982 after the direct cost of its products and services.
How much does Heart Test Laboratories spend on research and development?
Heart Test Laboratories spent $2.8 billion on research and development in fiscal 2026, 65,733,086.4% of revenue.
How fast is Heart Test Laboratories growing?
Revenue grew −29.9% a year on average over the last five fiscal years, from $0.0 million to $0.0 million.
What are Heart Test Laboratories's earnings per share?
Heart Test Laboratories earned $-3.94 per diluted share in fiscal 2026, compared with $-9.36 a year earlier.
When does Heart Test Laboratories's fiscal year end?
Heart Test Laboratories's fiscal year ends in April. The latest annual report covers the year ended April 30, 2026 and was filed on June 23, 2026.